JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Vitae Pharmaceuticals (VTAE) PT Raised to $23 at Wedbush
March 18, 2016 6:42 AM EDTWedbush analyst Liana Moussatos reiterated an Outperform rating and raised her price target on Vitae Pharmaceuticals (NASDAQ: VTAE) to $23.00 (from $20.00) after proof-of-concept for RAR-Related Orphan Receptor -t ( ROR t) inhibition was achieved, in their view.
Moussatos commented: "The randomized, double blind multiple ascending dose (MAD) Part II trial tested once-daily, orally-dosed... More
Stifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PT
March 17, 2016 6:27 AM EDTStifel upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Hold to Buy with a price target of $15.00, saying 43742 Data shows drug potential is significant, and toxic signal seems manageable.
Analyst Thomas Shrader commented, "Vitae release its eagerly awaited topline data for VTP-43742 and the drug is clearly active.... More
Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
March 16, 2016 4:06 PM EDTVitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including... More
Vitae Pharmaceuticals (VTAE) trading halted with news pending
March 16, 2016 4:01 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) trading halted with news pending.
... More